Clinical Trial Update: Study of Crizotinib for ROS1 and MET Activated Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating crizotinib for ROS1-rearranged and MET-activated non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (Xalkori) (crizotinib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Non-squamous Non-small-cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING